Price
Target price
€23.20
€23.20
-2.520%
-0.6
-2.520%
€33.94
29.01.26 / Tradegate
WKN: A1W2RM / Symbol: AGIO / Name: Agios / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Agios Pharmaceuticals Inc. Stock
A loss of -2.520% shows a downward development for Agios Pharmaceuticals Inc..
We see a rather positive sentiment for Agios Pharmaceuticals Inc. with 14 Buy predictions and 1 Sell predictions.
With a target price of 33 € there is a positive potential of 42.24% for Agios Pharmaceuticals Inc. compared to the current price of 23.2 €.
So far the community has only identified positive things for Agios Pharmaceuticals Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Agios Pharmaceuticals Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
C******** o* t** e**********
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Agios Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Agios Pharmaceuticals Inc. | -2.520% | -4.132% | 0.000% | -27.950% | 0.000% | -18.310% | -40.129% |
| Ironwood Pharmaceuticals | 1.000% | -7.306% | 52.632% | 15.341% | 52.632% | -60.879% | -52.791% |
| Novocure Ltd | 1.840% | -13.322% | -7.587% | -57.280% | -7.587% | -87.478% | -92.103% |
| Iovance Biotherapeutics Inc. | -0.460% | -3.678% | -9.465% | -64.041% | -9.465% | -70.719% | -94.052% |
Comments
Agios Pharmaceuticals (NASDAQ:AGIO) was given a new $40.00 price target on by analysts at Leerink Partners. They now have an "outperform" rating on the stock.
Show more
Ratings data for AGIO provided by MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Show more
Ratings data for AGIO provided by MarketBeat
News
Here's Why Shares in Agios Pharmaceuticals Popped Today
Shares in Agios Pharmaceuticals (NASDAQ: AGIO) soared by more than 18% as of 11 a.m. today. The move follows the company's receipt of approval from the Food and Drug Administration (FDA) for AQVESME
Why Shares in Agios Pharmaceuticals Got Crushed Today
Shares in Agios Pharmaceuticals (NASDAQ: AGIO) crashed by 50% by noontime today. The move comes as the market digests a mixed set of topline results from its Phase 3 trial (RISE UP) of its sickle
Agios (AGIO) Q2 Revenue Jumps 45%
Agios Pharmaceuticals (NASDAQ:AGIO), a biotechnology company focused on therapies for rare blood disorders, released its second quarter 2025 earnings on July 31, 2025. The headline was a notable